Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 8
2004 6
2005 12
2006 5
2007 6
2008 4
2009 3
2010 5
2011 2
2012 5
2013 3
2014 2
2015 1
2016 4
2017 3
2018 3
2020 1
2021 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Jo T, et al. Among authors: tanosaki r. Br J Haematol. 2023 Jul;202(2):256-266. doi: 10.1111/bjh.18831. Epub 2023 Apr 25. Br J Haematol. 2023. PMID: 37096915 Free article.
Tumor immunity against adult T-cell leukemia.
Kannagi M, Harashima N, Kurihara K, Ohashi T, Utsunomiya A, Tanosaki R, Masuda M, Tomonaga M, Okamura J. Kannagi M, et al. Among authors: tanosaki r. Cancer Sci. 2005 May;96(5):249-55. doi: 10.1111/j.1349-7006.2005.00050.x. Cancer Sci. 2005. PMID: 15904464 Free article. Review.
Adult T-cell leukemia: future prophylaxis and immunotherapy.
Kannagi M, Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Masuda M. Kannagi M, et al. Among authors: tanosaki r. Expert Rev Anticancer Ther. 2004 Jun;4(3):369-76. doi: 10.1586/14737140.4.3.369. Expert Rev Anticancer Ther. 2004. PMID: 15161436 Review.
[Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy].
Jo T, Henzan T, Tomizawa D, Yoshihara S, Kahata K, Yamada-Fujiwara M, Okuyama Y, Shiba N, Fujii K, Umezawa Y, Yamazaki R, Takeda W, Hanajiri R, Fukushima K, Mimura N, Ikemoto J, Iwaki K, Yonetani N, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Jo T, et al. Among authors: tanosaki r. Rinsho Ketsueki. 2023;64(5):331-337. doi: 10.11406/rinketsu.64.331. Rinsho Ketsueki. 2023. PMID: 37271521 Japanese.
Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial.
Okinaka K, Akeda Y, Inamoto Y, Fuji S, Ito A, Tanaka T, Kurosawa S, Kim SW, Tanosaki R, Yamashita T, Ohwada C, Kurata K, Mori T, Onozawa M, Takano K, Yokoyama H, Koh K, Nagafuji K, Nakayama K, Sakura T, Takahashi T, Oishi K, Fukuda T. Okinaka K, et al. Among authors: tanosaki r. Clin Microbiol Infect. 2023 Apr;29(4):482-489. doi: 10.1016/j.cmi.2022.12.007. Epub 2022 Dec 8. Clin Microbiol Infect. 2023. PMID: 36503114 Clinical Trial.
Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study.
Ikeda K, Ohto H, Okuyama Y, Yamada-Fujiwara M, Kanamori H, Fujiwara SI, Muroi K, Mori T, Kasama K, Iseki T, Nagamura-Inoue T, Fujii N, Ashida T, Kameda K, Kanda J, Hirose A, Takahashi T, Nagai K, Minakawa K, Tanosaki R. Ikeda K, et al. Among authors: tanosaki r. Transfus Med Rev. 2018 Jun 1:S0887-7963(18)30023-3. doi: 10.1016/j.tmrv.2018.05.005. Online ahead of print. Transfus Med Rev. 2018. PMID: 29891441 Free article. Review.
Comparison of cryoprotectants in hematopoietic cell infusion-related adverse events.
Ikeda K, Minakawa K, Yamahara K, Yamada-Fujiwara M, Okuyama Y, Fujiwara SI, Yamazaki R, Kanamori H, Iseki T, Nagamura-Inoue T, Kameda K, Nagai K, Fujii N, Ashida T, Hirose A, Takahashi T, Ohto H, Ueda K, Tanosaki R. Ikeda K, et al. Among authors: tanosaki r. Transfusion. 2022 Jun;62(6):1280-1288. doi: 10.1111/trf.16877. Epub 2022 Apr 9. Transfusion. 2022. PMID: 35396716
Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
Tsubokura M, Adegawa Y, Kojima M, Tanosaki R, Ohtake R, Kase Y, Iwashita N, Kasane M, Nakabayashi S, Takeuchi S, Kato K, Boku N, Kanemitsu Y, Okusaka T, Fujimoto H, Yonemori K, Ishiki H, Kawamura K, Satomi E, Matsushita H. Tsubokura M, et al. Among authors: tanosaki r. BMC Cancer. 2022 Mar 14;22(1):268. doi: 10.1186/s12885-022-09298-6. BMC Cancer. 2022. PMID: 35287609 Free PMC article.
88 results